Rosso R - Search Results

1

Oral ondansetron (GR38032F) for the control of acute and delayed cyclophosphamide-induced emesis.

Rosso R, Campora E, Cetto G, Fosser V, Marangolo M, Oliva C. Rosso R, et al. Anticancer Res. 1991 Mar-Apr;11(2):937-9. Anticancer Res. 1991. PMID: 1829602 Clinical Trial.

2

Prevention of delayed emesis with metoclopramide and dexamethasone in patients receiving moderately emetogenic cytotoxic treatment.

Chiara S, Campora E, Simoni C, Confalonieri M, Psilogenis M, Rosso R. Chiara S, et al. Among authors: rosso r. Anticancer Res. 1995 Jul-Aug;15(4):1597-9. Anticancer Res. 1995. PMID: 7654054 Clinical Trial.

3

Ondansetron and dexamethasone versus standard combination antiemetic therapy. A randomized trial for the prevention of acute and delayed emesis induced by cyclophosphamide-doxorubicin chemotherapy and maintenance of antiemetic effect at subsequent courses.

Campora E, Giudici S, Merlini L, Rubagotti A, Rosso R. Campora E, et al. Among authors: rosso r. Am J Clin Oncol. 1994 Dec;17(6):522-6. Am J Clin Oncol. 1994. PMID: 7977174 Clinical Trial.

4

[Tropisetron versus ondansetron in the prevention and control of emesis in patients undergoing chemotherapy with FAC/FEC for metastatic or surgically treated breast carcinoma].

Campora E, Simoni C, Rosso R. Campora E, et al. Among authors: rosso r. Minerva Med. 1994 Jan-Feb;85(1-2):25-31. Minerva Med. 1994. PMID: 8152575 Clinical Trial. Italian.

5

Mitoxantrone in elderly women with advanced breast cancer: a phase II study.

Repetto L, Simoni C, Venturino A, Biancardi V, Gasco M, Campora E, Rosso R. Repetto L, et al. Among authors: rosso r. Anticancer Res. 1995 Sep-Oct;15(5B):2297-300. Anticancer Res. 1995. PMID: 8572641 Clinical Trial.

6

Metastatic breast cancer patients failing first-line, anthracycline-containing chemotherapy: is further therapy of benefit?

Campora E, Gardin G, Gasco M, Rosso R, Santi L. Campora E, et al. Among authors: rosso r. Anticancer Res. 1999 Jul-Aug;19(4C):3429-32. Anticancer Res. 1999. PMID: 10629630

7

Intraperitoneal chemotherapy with carboplatin and interferon alpha in the treatment of relapsed ovarian cancer: a pilot study.

Repetto L, Chiara S, Guido T, Bruzzone M, Oliva C, Ragni N, Conte PF, Rosso R. Repetto L, et al. Among authors: rosso r. Anticancer Res. 1991 Jul-Aug;11(4):1641-3. Anticancer Res. 1991. PMID: 1746921

8

Control of refractory, chemotherapy-induced emesis with the serotonin antagonist ondansetron (GR38032F).

Campora E, Vidili G, Oliva C, Ardizzoni A, Rosso R. Campora E, et al. Among authors: rosso r. Oncology. 1991;48(5):403-5. doi: 10.1159/000226969. Oncology. 1991. PMID: 1836058

9

Oral ondansetron (GR 38032F) for the control of CMF-induced emesis in the outpatient.

Campora E, Oliva C, Mammoliti S, Cetto GL, Fosser V, Marangolo M, Rosso R. Campora E, et al. Among authors: rosso r. Breast Cancer Res Treat. 1991 Oct;19(2):129-32. doi: 10.1007/BF01980943. Breast Cancer Res Treat. 1991. PMID: 1836746 Clinical Trial.

10

Prognostic factors in node positive primary breast cancer patients treated with adjuvant CMF.

Campora E, Pronzato P, Amoroso D, Bertelli GF, Venturini M, Baldini E, Brunetti I, Sertoli MR, Conte P, Rosso R. Campora E, et al. Among authors: rosso r. Anticancer Res. 1992 Sep-Oct;12(5):1555-8. Anticancer Res. 1992. PMID: 1444221

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

864 results

Search Page

Filters